translation agency

NLM AIDSLINE
Influence of pre-treatment factors on outcome of interferon-alpha treatment of patients with chronic hepatitis C.
Weiland O; Braconier JH; Fryden A; Norkrans G; Reichard O; Uhnoo I;
December 30, 1999
Scand J Infect Dis. 1999;31(2):115-8. Unique Identifier : AIDSLINE

A total of 172 Swedish patients treated with interferon-alpha for at least 24 weeks and followed-up > or =24 weeks after treatment was stopped were analysed for pre-treatment factors of importance for achieving a virological sustained response (SR). Furthermore, the predictive value for a virological SR of a positive or negative HCV RNA test at week 12 of treatment was evaluated. A low baseline viral load and genotype non-1b were pre-treatment factors indicating a favourable response. Thus, 44% (38/86) of patients with a low baseline viral load vs. only 16% (14/86) of those with a high viral load had a virological SR (p<0.0001). Of patients with a negative qualitative HCV RNA test after 12 weeks of interferon treatment, 46% (44/95) had virological SR, whereas only 5.9% (4/68) of those with a positive test had (p<0.0001). Prolonged ( > 6 months) treatment with interferon-alpha tended to increase the chance of virological SR (p<0.052).

CLINICAL TRIAL JOURNAL ARTICLE RANDOMIZED CONTROLLED TRIAL Adolescence Adult Age Factors Aged Alanine Transaminase/METABOLISM Female Genotype Hepatitis C-Like Viruses/GENETICS/*PHYSIOLOGY Hepatitis C, Chronic/*DRUG THERAPY Human Interferon Alfa, Recombinant/THERAPEUTIC USE Interferon-alpha/*THERAPEUTIC USE Liver/ENZYMOLOGY Male Middle Age RNA, Viral/BLOOD Sex Factors Treatment Outcome *Viral Load

www.aegis.org